[Happiness and the meaning of life].

V. Frankl

1994-10-01

Abstract:

What problem does this paper attempt to address?

Comparison the Effectiveness and Safety of Letrozolestimulated and Hormone Replacement Treatment in Endometrial Preparation for Frozen Embryo Transfer in Patients with Polycystic Ovary Syndrome

X. Wang,Y. Li,S. Cai,X. Li,Y. Tang,K. Luo,S. Zhang,G. Lin,F. Gong

DOI: https://doi.org/10.1093/humrep/dead093.941

IF: 6.1

2023-01-01

Human Reproduction

Abstract:Study question Whether letrozole-stimulated protocol has advantages over hormone replacement therapy (HRT) in frozen embryo transfer in patients with polycystic ovary syndrome (PCOS)? Summary answer Letrozole-stimulated protocol is more suitable for endometrial preparation than HRT in patients with PCOS, which can increase the live birth rate and reduce pregnancy complications. What is known already The current routine endometrial preparation protocol for women with PCOS is HRT. However, HRT is expensive, and recent studies have found HRT may increase the risk of adverse maternal and neonatal complications such as hypertensive disorders of pregnancy. Letrozole induces mono-ovulatory and has no antiestrogenic effect, and has been found to increase live birth rate compared with clomiphene in fresh embryo cycles. However, Letrozole is rarely used in frozen embryo cycles. Whether letrozole-stimulated protocol is suitable for frozen embryo transfer in patients with PCOS and for whom is suitable is still lack of evidence. Study design, size, duration This is a retrospective cohort study involving all frozen embryo transfer cycles with letrozole-stimulated and HRT for PCOS during the period from August 2018 to December 2020 at a tertiary care center. Participants/materials, setting, methods A total of 2011 letrozole-stimulated cycles and 2211 HRT cycles were included in the analysis. Multivariate Logistic regression was used to analyze the differences in clinical pregnancy rate, live birth rate, miscarriage rate, the incidence of other pregnancy and obstetric outcomes between letrozole-stimulated protocol and HRT after adjusting for possible confounding factors. Subgroup analysis was used to explore the population for which letrozole-stimulated protocol was suitable. Main results and the role of chance After adjusting for confounding, letrozole-stimulated protocol increased the clinical pregnancy rate (OR,1.44; 95%CI,1.21-1.70), live birth rate (OR,1.49; 95%CI,1.27-1.74) and reduced the incidence of miscarriage (OR, 0.71; 95%CI,0.55-0.92), hypertensive disorders of pregnancy (OR, 0.66; 95%CI,0.45,0.98), gestational diabetes mellitus (OR,0.75; 95%CI,0.57,0.98) and cesarean section (OR,0.78; 95%CI,0.61,0.99) than HRT. There were no significant differences in other outcomes such as preterm birth, small for gestational age, and large for gestational age between the two endometrial preparation protocols. Subgroup analysis according to maternal age, BMI, insulin resistance and PCOS classification showed that the live birth rate of letrozole-stimulated protocol was significantly higher than that of HRT in all subgroups. Limitations, reasons for caution This study is a retrospective study, the population characteristics of the two endometrial preparation protocols existed differences. Although multivariate logistic regression was used to adjust some factors, the interference of known and unknown factors on the outcomes cannot be completely avoided. Wider implications of the findings This retrospective study found letrozole-stimulated protocol has more advantages than HRT, which can improve the live birth rate and reduce the incidence of hypertensive disorders of pregnancy, gestational diabetes mellitus in patients with PCOS. High-quality well-powered randomised clinical trials and possible mechanistic studies are needed to further validate this conclusion. Trial registration number NA
Letrozole Stimulation in Endometrial Preparation for Cryopreserved–thawed Embryo Transfer in Women with Polycystic Ovarian Syndrome: A Pilot Study

Yan-Jun Hu,Yue-Zhou Chen,Yi-Min Zhu,He-Feng Huang

DOI: https://doi.org/10.1111/cen.12280

2013-01-01

Clinical Endocrinology

Abstract:OBJECTIVE:To study the efficiency of letrozole, an aromatase inhibitor, in endometrial preparation for cryopreserved-thawed embryo transfer (FET) in women with polycystic ovarian syndrome (PCOS).DESIGN:Retrospective observational study.PATIENTS:One hundred and twenty patients with PCOS who met the inclusion criteria for the study.MEASUREMENTS:We assessed in vitro fertilization outcomes in one hundred and twenty patients with PCOS (148 cycles) who were prepared for and underwent FET between June 2011 and December 2012. Patients were prepared for FET using artificial hormone cycles induced with oestrogen and progesterone supplementation (n = 76), letrozole stimulation (n = 40) or hMG stimulation (n = 32).RESULTS:There were no differences in demographic characteristics between the groups, except that the letrozole group had a higher incidence of embryo transfer failure in the past. The letrozole stimulation group had a significantly higher maximal endometrial thickness and significantly higher rates of clinical pregnancy per transfer, ongoing pregnancy per transfer and implantation, compared with the artificial and hMG stimulation groups. Differences in these parameters between the artificial and hMG stimulation groups were not significant.CONCLUSION:Using letrozole stimulation in endometrial preparation for cryopreserved-thawed embryo transfer in patients with PCOS may be associated with better outcomes than using hormonal manipulation or hMG stimulation.
Comparison of Letrozole Versus Combination Letrozole and Clomiphene Citrate (CC) for Ovulation Induction in Sub Fertile Women with Polycystic Ovarian Syndrome (PCOS)—An Open Label Randomized Control Trial

Sharmistha Sarkar,Nivedita Gupta,Treasa Joseph,Bijesh Yadav,Aleyamma T. Kunjummen,Mohan S. Kamath

DOI: https://doi.org/10.1007/s43032-024-01743-0

2024-11-07

Reproductive Sciences

Abstract:To evaluate the effectiveness of Letrozole and Clomiphene (CC) combination versus Letrozole alone for ovulation induction in infertile women with PCOS. This was an open label randomized controlled trial conducted between September 2020 and March 2023 at a tertiary level hospital. Women with a diagnosis of infertility and PCOS were included. Participants were randomized in a 1:1 ratio, to either the combination of 2.5 mg letrozole and 50 mg Clomiphene Citrate (CC) daily or 2.5 mg letrozole alone from 2nd to 6 th day of menstrual cycle for up to three treatment cycles. The primary outcome was ovulation rate per cycle. The secondary outcomes included ovulation rate per woman randomised, cumulative pregnancy and live birth rates. A total of the 120 participants, 59 women in Letrozole and CC arm (intervention) and 61 women in the Letrozole alone arm (control) were recruited. The woman per cycle ovulation rate following Letrozole and CC combination versus Letrozole alone (71/92 (77.2%) vs. 52/83 (62.6%), RR 1.43, 95%CI 0.99 to 2.06) but was not statistically significant. A per ITT analysis, the clinical pregnancy rate per woman randomized (16/61(26.2%) vs. 13/59(22%), RR 1.12, 95%CI 0.76 to 1.64) and live birth rate per woman randomized (10/61(16.4%) vs 11/59(18.6%), RR 0.92, 095%CI 0.57 to 1.50) did not differ significantly between Letrozole and CC versus Letrozole group. There was no significant improvement in ovulation, clinical pregnancy, or live birth rates with a combination of letrozole and CC versus letrozole alone in per woman randomized with PCOS.

obstetrics & gynecology,reproductive biology
Use of letrozole versus clomiphene citrate combined with gonadotropins for ovulation induction in infertile women with polycystic ovary syndrome: a pilot study

Amitoj Athwal,Ratnabali Chakravorty,Dipanshu Sur,Rupam Saha

DOI: https://doi.org/10.18203/2320-1770.ijrcog20174068

2017-08-28

Abstract:Background: The aim of the study was to evaluate the efficacy of letrozole and clomiphene citrate (CC) in gonadotropin-combined for ovulation stimulation in women with polycystic ovary syndrome (PCOS). It was a prospective pilot study.Methods: This prospective trial included 124 patients of infertile women with PCOS. Letrozole dose of 5 mg/day (n = 65) or a CC dose of 100 mg/day (n = 59) was given on day 3 to day 7 of the menstrual cycle, combined with gonadotropin i.e. follicle stimulating hormone (FSH) at a dose 75 IU every day starting on day 7 and continued to day 9. Main outcome measures were occurrence of ovulation, number of mature follicles, serum estradiol (E2) and endometrial thicknesses on the day of human chorionic gonadotropin (hCG), and pregnancy rates.Results: The clinical profile including mean age, duration of infertility, BMI, baseline FSH, LH and E2 of patients belonging to both groups were comparable. The numbers of mature follicles (4.3±0.3 vs. 2.9±0.7) were significantly higher in letrozole+FSH group. Serum E2 levels on the day of hCG (301.78±85.7 vs. 464.7±72.9 pg/mL) were significantly lower in the letrozole+FSH group. Significant differences were found in endometrial thickness measured on the day of hCG in letrozole+FSH group (p=<0.0001). The rate of ovulation was higher in letrozole+FSH group and it was marginally statistically significant (p=0.040). The rate of pregnancy was slightly greater in the letrozole+FSH group (17.85% versus 13.33%), although not statistically significant.Conclusions: Letrozole in combination with FSH appears to be a suitable ovulation inducing agent versus CC with FSH in PCOS. This combination may be more appropriate in patients who are particularly sensitive to gonadotropin.

English Else
Evaluation of effectiveness of Letrozole in treatment of infertility in women with polycystic ovary syndrome

Jasrin Akter Mile,Mashuma Munni,Dilara Rahman,Tahamina Parvin,Shanaz Pervin

DOI: https://doi.org/10.3329/cemecj.v7i1.70827

2024-01-21

Abstract:Background: Polycystic ovary syndrome (PCOS) is the most common endocrine and metabolic disease, characterized by hyperandrogenism, oligomenorrhea, and polycystic ovaries. PCOS is one of the most causes that affect the women of childbearing age, and often leads to infertility. Various managements were proposed for infertile women with PCOS. However, the optimal management option has not been addressed satisfied. Although multiple treatments including weight reduction, clomiphene citrate, metformin, gonadotropins, and ovary cauterization have been reported to treat such condition, the efficacy still has insufficient evidence to support. Objectives: Purpose of this study was to evaluate the effectiveness of Letrozole in treatment of infertility in women with polycystic ovary syndrome. Materials & method: This study was carried out to assess the effectiveness of letrozole and on pregnancy outcomes including the ovulation induction, pregnancy rate, and endometrial thickness in infertile women with polycystic ovarian syndrome (PCOS). Total 106 infertile PCOS patients were recruited and allocated in two groups, Group-L (received letrozole at 2.5 mg twice daily on the 3rd–5th days of menstrual cycle for 5 consecutive days), Group-G 75 U/d−1 gonadotropin through intramuscular injection for 5 days starting from the third day of menstrual cycle). All patient in both arm completed treatment and follow-up. Patients in both groups were treated up to 5 treatment cycles. During follow up, transvaginalultrasonogram (TVS) was performed to see the details of the follicles and the endometrium. Data was processed and analysed with the help of computer program SPSS and Microsoft excel. Quantitative data expressed as mean and standard deviation and qualitative data as frequency and percentage. Comparison was done by tabulation and graphical presentation in the form of tables, pie chart, graphs, bar diagrams, histogram & charts etc. Result: Mean age of the patient was 26.3 ± 5.7 years in group-L and 25.9 ± 6.1 years in group-G. There were no statistical significant differences between the 2 groups regarding age, body weight, height, body mass index (BMI). Present study results showed that patients who received letrozole exert better outcomes in primary endpoint, including ovulation rate (86.7% in group-L & 62.2% in group-G, P =0.004), endometrial thickness (9.3 ± 1.1 mm in group-L & 8.5 ± 1.1 mm in group-G, P = 0.003) and pregnancy rate (64.1% in group-L & 30.1% in group-G, P =0.005). Abortion rate (till the end of 12th week) and multiple pregnancy rate were higher in group-G, but result were non-significant in between groups. Live birth rate in the letrozole group was higher 29(54.7%) than group-G 14(26.4%), the difference was statistically significant (P < .05). Conclusion: Patients who took Letrozole had significantly higher endometrial thickness than other group. Due to the higher pregnancy rate and lower incidence of abortion or multiple pregnancy, letrozole can be an effective for the treatment of anovulatory subfertility of the PCOS patients. Central Medical College Journal Vol 7 No 1 January 2023 Page: 13-19
Trial design and protocol of randomized controlled trial comparing the efficacy of combined letrozole and clomiphene versus only letrozole as a method of ovulation induction in women with polycystic ovarian syndrome (CCLOP trial)

Soumya R. Panda,Vijayan Sharmila,Vinoth Kumar Kalidos,Smrutismita Hota

DOI: https://doi.org/10.18203/2349-3259.ijct20221874

2022-07-26

International Journal of Clinical Trials

Abstract:Background: Both clomiphene (CC) and letrozole are commonly used oral ovulation induction agents, with different mechanism of action. Apart from letrozole or CC, options for ovulation induction in polycystic ovarian syndrome (PCOS) patients are limited and thus leaving the use of gonadotropin injections as the only option of ovulation induction in these patients. The objective of this study is to evaluate the efficacy of combined therapy of letrozole and CC compared to the use of letrozole alone to achieve ovulation in infertile women with PCOS. Methods: This will be a single-centre, double arm, triple-blind randomized controlled trial. The study was conducted after taking approval from institutional ethics committee and was prospectively registered with the clinical trials registry- India. Women were randomly assigned to receive a combination of 2.5 mg letrozole and placebo daily or a combination of 2.5 mg letrozole and 50 mg CC daily on cycle days 3–7 for one treatment cycle. Conclusions: If combination of clomiphene and letrozole is proved to be more efficacious than letrozole alone, there will be several breaks through advantages in the management of infertility. The novel method of ovulation induction with combined letrozole and clomiphene will bring down overall cost of infertility treatment. Trial registration: The study is prospectively registered with the clinical trials registry- India CTRI/2020/09/028012.
Effects of letrozole alone or in combination with gonadotropins on ovulation induction and clinical pregnancy in women with polycystic ovarian syndrome: a systematic review and meta-analysis of randomized controlled trials

Saeed Baradwan,Faisal Al-Shalhoub,Majed Saeed Alshahrani,Samah Himayda,Rayan AlSghan,Hussein Sabban,Inass Hassan Ahmad,Marwa Fekry Mohamed El Sayed,Entesar Omar Mohamad,Abdulhadi A. AlAmodi,Ahmed Mohamed Abdelhakim,Kareem Shaheen

DOI: https://doi.org/10.1007/s42000-024-00531-4

2024-01-28

HORMONES

Abstract:Objective To compare letrozole in combination with gonadotropins versus letrozole monotherapy in ovulation induction and clinical pregnancy among infertile women with polycystic ovarian syndrome (PCOS). Methods Several databases were searched for available clinical trials from inception until March 2023. We selected randomized controlled trials (RCTs) that compared sequential letrozole/gonadotropin versus letrozole alone among infertile women who met the Rotterdam criteria for PCOS. RevMan software was used to perform our meta-analysis. Our primary outcomes were ovulation and clinical pregnancy rates. Our secondary outcomes were endometrial thickness, number of mature follicles (diameter ≥ 18 mm), and incidence of miscarriage and ovarian hyperstimulation syndrome (OHSS). Results Six RCTs were retrieved with a total number of 723 patients. The ovulation and clinical pregnancy rates were significantly higher among the letrozole/gonadotropin group versus the letrozole monotherapy group ( p < 0.001). In addition, there were significant improvements in endometrial thickness and number of mature follicles in the letrozole/gonadotropin group. There were no significant differences between the two groups regarding incidence of miscarriage and ovarian hyperstimulation syndrome. Conclusion Letrozole in combination with gonadotropin is superior to letrozole alone in improving ovulation induction and clinical pregnancy among PCOS patients. More trials are required to confirm our findings.

endocrinology & metabolism
Comparison of Letrozole and Clomiphene Citrate in Pregnancy Outcomes in Patients with Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis

Ahmed Abu-Zaid,Abdulrahim Gari,Hussein Sabban,Majed Saeed Alshahrani,Khalid Khadawardi,Ehab Badghish,Rayan AlSghan,Ibtihal Abdulaziz Bukhari,Abdullah Alyousef,Mohammed Abuzaid,Saud Abdullah Alsharif,Osama Alomar,Aliyah Hadi Alamery,Saeed Baradwan

DOI: https://doi.org/10.1007/s43032-023-01404-8

Abstract:Clomiphene citrate (CC) and letrozole are the predominant medical interventions for the management of infertility in patients with polycystic ovary syndrome (PCOS). To comprehensively summarize the evidence, a systematic review and meta-analysis of randomized clinical trials (RCTs) was carried out to assess the effect of letrozole and CC on pregnancy outcomes in PCOS patients. We searched PubMed/MEDLINE, Scopus, and Cochrane Central Register of Controlled Trials from inception to January 2023. We included RCTs conducted on PCOS women comparing letrozole to CC and assessing endometrial thickness, the number and size of follicles, and ovulation and pregnancy rates. The endpoints were summarized as risk ratio (RR) or standardized mean difference (SMD) with 95% confidence interval (CI) using the random-effects model. Heterogeneity was examined using the I2 statistic. Fifty trials met our inclusion criteria. The mean endometrial thickness was significantly higher in the letrozole group compared to CC group (SMD: 0.89; 95% CI: 0.49, 1.28; I2=97.72%); however, the number of follicles was higher in the CC group (SMD: -0.56; 95% CI: -0.96, -0.17; I2=96.34%). Furthermore, letrozole intake induced higher ovulation rate (RR: 1.20; 95% CI: 1.13, 1.26; I2=54.49%) and pregnancy rate (RR: 1.44; 95% CI: 1.28, 1.62; I2=65.58%) compared to CC. Compared to CC, letrozole has a positive effect on endometrial thickness, monofollicular development, and ovulation and pregnancy rates suggesting that letrozole may be a strong alternative to CC as a first-line medical intervention for chronic anovulation in PCOS women. Larger studies are warranted to further clarify these findings.
Adrenergic stimulation of vascular prostacyclin: role of alpha 1-receptors in smooth muscle cells.

J. Boeynaems,D. Demolle,N. Galand

IF: 5.195

European Journal of Pharmacology

Abstract:Epinephrine and norepinephrine (1-10 microM) stimulated the release of prostacyclin (PGI2) from the rabbit aorta in vitro. The stimulation was maintained for at least 2 h in the continuous presence of epinephrine. Phenylephrine mimicked this effect, whereas the selective alpha 2-agonist UK-14,304 was completely ineffective. The action of epinephrine was abolished by prazosin (1 microM) and was maintained in the presence of yohimbine. Epinephrine or phenylephrine neither increased the basal release of PGI2 from bovine aortic endothelial cells nor potentiated the stimulatory action of adenine nucleotides, which is mediated by P2-purine receptors. The response to epinephrine was lost in freshly deendothelialized strips of rabbit aorta, possibly because of cyclooxygenase self-inactivation. The response recovered however following overnight incubation of these strips in a cell culture medium. The response to epinephrine was mimicked by neither phorbol 12-myristate,13-acetate nor ionophore A23187. It was not inhibited by pretreatment with pertussis toxin. It is concluded that adrenergic agents stimulate the vascular production of PGI2, by activating alpha 1-receptors located on smooth muscle cells.
Letrozole combined with low dose highly purified human menopausal gonadotropin for ovulation induction in clomiphene citrate-resistant infertile women with polycystic ovary syndrome:a prospective study

Yue Zhao,Xiangyan Ruan,Yanglu Li,Juan Du,O Alfred

DOI: https://doi.org/10.3969/j.issn.1006-7795.2016.04.004

2016-01-01

Abstract:Objective To evaluate the efficacy, safety and feasibility of letrozole ( LTZ) combined with low dose highly purified human menopausal gonadotropin ( Hp-HMG ) in clomiphene citrate ( CC )-resistant infertile women with polycystic ovary syndrome ( PCOS ) . Methods Totally 120 infertile women with PCOS with CC resistance were enrolled for ovulation induction by LTZ combined with low dose Hp-HMG, together with 237 cycles. The primary study endpoints were the clinical pregnancy rate, the ovulation rate and the percentage of monofollicular development. The secondary efficacy endpoints included the number of ovulated follicles, serum level of estradiol and luteinizing hormone ( LH) and endometrial thickness on the day of gonadotropin releasing hormone agonist ( GnRH-a) triggering. The main safety parameters were the incidence of adverse events, including the early abortion, ovarian hyperstimulation syndrome ( OHSS ) , and multiple pregnancy. Results The rate of cycle ovulation was 96. 2% (228/237), the percentage of monofollicular development was 70%(166/237), cycle cancellation rate was 1. 3% (3/237) and anovulation rate was 3. 8% (9/237);237 cycles achieved the periodic single pregnancy rate was 32. 9% (75/228), the early abortion rate was 5. 3% (12/228). Two twin gestation and 1 ectopic pregnancy; In 120 patients, the rate of cumulative clinical pregnancy was 65% (78/120). No severe OHSS, multiple pregnancy, local or systemic side effects were seen. Conclusion Letrozole combined with low dose Hp-HMG maybe an effective and safe choice for reducing hyperstimulation and increasing pregnancy rate for ovulation induction in CC-resistant women with PCOS.
Comparison of clomiphene citrate and letrozole for ovulation induction in women with polycystic ovary syndrome: a prospective randomized trial

Chang Liu,Guimei Feng,Wei Huang,Qiuyi Wang,Shiyuan Yang,Jing Tan,Jing Fu,Dong Liu

DOI: https://doi.org/10.1080/09513590.2017.1332174

2017-05-30

Gynecological Endocrinology

Abstract:To compare the therapeutic efficacy of clomiphene citrate (CC) and letrozole (LE) on ovulation, pregnancy, and live birth in women with polycystic ovary syndrome (PCOS); and to ensure if LE can replace CC as the first-line therapy for ovulation induction in these women. This is a prospectively, randomized, controlled trial in the tertiary hospital. Two-hundred and sixty-eight anovulatory PCOS patients were treated by CC or CC plus metformin and LE or LE plus metformin for three continuous cycles or conception; their ovulation rates, pregnancy rates, and live birth rates were calculated and compared. No significant difference was noted among the four groups regarding to the baseline data of clinical manifestations, serum sex hormone levels, and serum insulin levels. A total of 240 patients completed the therapies. The ovulation rate was significantly higher in the group LE than the group CC; however, no significant difference was noted between the groups LE and CC, CC, and CC + MET, or LE and LE + MET in the pregnancy rate, abortion rate, and live birth rate. No birth defect was found in the total of 63 newborns. CC regimen was still recommended to be the first-line therapy of ovulation induction for PCOS.

endocrinology & metabolism,obstetrics & gynecology
Analysis of individualized letrozole therapy for polycystic ovary syndrome patients resistant to clomiphene

Shunyu LIU,Xiangyan RUAN,Yulan LIU

2015-01-01

Abstract:Objective To investigate the clinical efficacy of individualized letrozole therapy for polycystic ovary syn -drome ( PCOS) patients resistant to clomiphene .Methods A total of 52 PCOS patients resistant to clomiphene were en-rolled in the current study .They were administrated with individualized letrozole therapy , while their follicle growth was strictly monitored.Then, the following information was recorded to analyze clinical efficacy:the weekly dosage of letro-zole, the number of dominant follicles , hCG injection date , endometrial thickness , and the rates of ovulation and preg-nancy.Results The individualized letrozole therapy was applied for 102 cycles.The average dosage of letrozole was (42.73 ±13.73) mg [(17.09 ±5.49) tablets].The rates of ovulation and pregnancy were 91.17% and 65.38%, respectively .No ovarian hyperstimulation syndrome was reported .Conclusion Individualized letrozole therapy can ef-fectively improve the rates of ovulation and pregnancy for PCOS patients resistant to clomiphene under strictly monitoring conditions.
[Pharmacobezoar of the stomach as a complication of treatment of duodenal ulcer (author's transl)].

A. Wiernikowski,J. Bogdał,M. Klasa

Abstract:
Extended Letrozole Regimen for Treatment of Clomiphene Resistant Polycystic Ovary Syndrome Patients

Ahmed Morad,Ehab Barakat,Ahmed Bayomey,Manal Hassen

DOI: https://doi.org/10.21608/bmfj.2021.18571.1126

2021-10-17

Benha Medical Journal

Abstract:Background: Polycystic Ovary Syndrome (PCOS) is one of the most common causes of an-ovulatory, 4-7% of women, The aim of the study is to compare the extended letrozole regimen with the classical one in treatment of CC resistant PCO patients, Subjects and Methods: 60 infertile, PCO and CC resistant women were divided randomly into 2 groups, group I, (short letrozole therapy) received 2.5mg twice daily from 2nd day of cycle for 5 days and repeated for 3 cycles (classical regimen)and group II, (long letrozole therapy) treated by 2.5mg once daily from 2nd day of cycle for 10 days and repeated for 3 cycles (extended regimen). Follicular growth and endometrial thickness monitoring, in all patients was performed regulary by trans-vaginal ultrasound. On day 10 of the cycles. HCG injection (5,000 IU IM) was given when at least one follicle measured ≥ 18mm followed by timed intercourse. Results: ovulation after treatment among group I (56.7%) compared to group II (63.3%) (P=0.598). Total number of follicles during stimulation was significantly greater in group I (6.51 ±0.78) vs. (4.2 ±0.81) in group II; (P=0.001). The mean ± SD of endometrial thickness at HCG injection among group I and group II was 8.4±1.76 mm and 8.83±1.45 mm respectively without significant difference between them (P=0.076). Pregnancy rate in group I was (13.3%) while (26.7%) in group II showing significant statistical difference. (P = 0.017). Conclusion: Treatment with long letrozole protocol can produce more mature follicles and subsequently increased pregnancy rate than the short letrozole therapy
Comparison the effects of letrozole and clomiphene citrate on the endocrinological profile in women with polycystic ovarian syndrome

LI Hong-Zhen,QIAO Jie

2012-01-01

Abstract:Objective To compare the clinical effects and endocrinological environment between letrozole and clomiphene citrate(CC) stimulated cycles in women with polycystic ovarian syndrome(PCOS).Methods A prospective,case-control study was conducted.Infertile women with PCOS were given letrozole 2.5 mg per day or CC 50 mg per day for five days.Timed intercourse or intrauterine insemination(IUI) was performed on the day of follicles rupture.Results Both ovulation rate and pregnancy rate were not different between two groups.Letrozole group had less mature follicles.Thicker endometriums and lower E2 levels were seen in the letrozole group.Androstenedione was significantly higher in the letrozole group on the cycle day 8.Conclusion Letrozole is effective in ovulation stimulation.It might be helpful in reduction of multiple pregnancy.The change of androgen induced by letrozole might adversely influence the pregnancy rate in women with PCOS.
Low dose-extended letrozole versus double dose-short letrozole protocol for ovulation induction in polycystic ovary syndrome

Shirin Jahan,Farzana Deeba,Shakeela Ishrat,Jesmine Banu,Chalontika Rani,Sumaiya Akter,Sohely Nazneen,Nishat Jahan

DOI: https://doi.org/10.18203/2320-1770.ijrcog20222786

2022-10-28

Abstract:Background: Letrozole, an aromatase inhibitor has been regarded as the first line drug for ovulation induction in anovulatory PCOS patients because of its monofollicular growth and there is no chance of hyperstimulation by letrozole. Traditional protocol of letrozole includes administration of letrozole for 5 days in first half of follicular phase which induces ovulation in 61.7% cases. Few recent studies have shown that extended letrozole protocol causes more follicles to grow and induces more ovulation than the traditional protocol. The aim was to compare the effects of low dose-extended letrozole protocol and double dose-short letrozole protocol for ovulation induction in infertile PCOS patients.Methods: A randomized controlled trial (RCT) was conducted in the department of reproductive endocrinology and Infertility at Bangabandhu Sheikh Mujib Medical University (BSMMU) on seventy infertile polycystic ovary syndrome patients. Low dose-extended letrozole group or experimental group received tablet letrozole 2.5 mg daily for 10 days and double dose-short letrozole group or control group received tab. Letrozole 5 mg daily for 5 days starting from the 2nd day of menstrual cycle or withdrawal bleeding. The ovarian response was assessed by folliculometry on day 12 of menstrual cycle by transvaginal sonography for measurement of total number of growing follicles, biggest follicle size and endometrial thickness. Mid luteal serum progesterone was measured on day 21-23 to confirm ovulation.Results: The mean number of growing follicle was 1.440.95 versus 0.990.65 in low dose-extended letrozole group and double dose-short letrozole group respectively generating p value of 0.001. The mean size of the dominant follicle at day 12 was greater in low dose-extended letrozole group than the other displaying 17.69±3.63 mm and 16.6±3.49 mm respectively but the difference was not statistically significant. The number of ovulating patients was greater in low dose-extended letrozole group (76.5% versus 71.9%), but without significant statistical difference. Pregnancy rate was insignificantly greater in low dose-extended letrozole group (23.5% versus 18.8%) as well.Conclusions: Low dose-extended letrozole protocol produces more multifollicular growth and larger size dominant follicle with a trend to raise the ovulation rate and pregnancy rate, though insignificantly.
Effects of letrozole alone or letrozole in combination with low-dose intramuscular injection of human menopausal gonadotropin on ovulation and pregnancy of 150 patients with polycystic ovary syndrome

Kaiser Ahmad,Ufaque Muzaffar,Sadiya Bashir,Farhat Jabeen

DOI: https://doi.org/10.18203/2320-1770.ijrcog20205763

2020-12-26

Abstract:Background: Objective of the study was to explore the effects of letrozole (LE) in combination with low-dose intramuscular injection of human menopausal gonadotropin (HMG) on the ovulation induction and pregnancy of patients with polycystic ovary syndrome (PCOS).Methods: The study comprised of 150 couples who were randomly divided into two groups of 75 each. Group “A” received letrozole (LE) in a dose of 2.5 mg to 5mg /d. LE was started orally starting on 3rd to 5th day of menstrual cycle for 5 consecutive days. Group “B” received letrozole in a dose of 2.5 to 5 mg/day starting on the 3rd to 5th day of menstrual cycle for 5 consecutive days. Starting from the day of oral administration of letrozole, 75 IU HMG was injected intramuscularly on alternate days for 5 consecutive doses. The ovulation induction parameters and pregnancy outcomes were observed.Results: The Group A (LE group) had the most completed cycle (310 cycles), 157 (52.3%) of which had ovulation. The Group B (LE+HMG) group completed the fewest cycles (258 cycles), with 168 (65.1%) of them ovulating. This difference was statistically significant (P<0.05). On HCG injection day, both the endometrial thickness (11.5±1.2) and number of mature follicles (2.1±1.3) of the Group B were significantly higher than those of Group A (P 0.05) The pregnancy rate of the Group B was 54.7%, which was significantly higher than that of the Group A (29.3 %) (P<0.05) The average medication cycle of the Group B group was significantly shorter than that of the Group A (P<0.05).Conclusions: The regimen using LE in combination with low-dose intramuscular injection of HMG has satisfactory therapeutic effects on ovulation induction, short medication cycle and high clinical pregnancy rate, which is promising for treating patients with PCOS infertility.
Is combined letrozole and clomiphene superior to either as monotherapy: a systemic review and meta-analysis based on clinical trials

Anusha Ashkar,Bismeen Jadoon,Mirza Mehmood Ali Baig,Shayan A. Irfan,Mona El-Gayar,Fatima Zulfiqar Siddiqui

DOI: https://doi.org/10.1080/09513590.2024.2405114

2024-09-21

Gynecological Endocrinology

Abstract:Objective This research was conducted to assess the therapeutic advantage of combined letrozole and clomiphene citrate versus monotherapy for polycystic ovarian syndrome (PCOS) patients.

endocrinology & metabolism,obstetrics & gynecology
Analysis of the Effect of Letrozole Tablets Combined with Menotrophin in the Treatment of Infertility of Polycystic Ovary Syndrome

Caixia Liu

DOI: https://doi.org/10.26689/aogr.v2i3.7665

2024-07-22

Abstract:Objective: To investigate the clinical effects of Letrozole tablets combined with Menotrophin in infertile patients with polycystic ovary syndrome (PCOS). Methods: The time period of the study was from February 2023 to February 2024; 62 cases of PCOS infertility patients admitted to our hospital were selected and divided into an observation group (n = 31) and a control group (n = 31) by using the method of a random drawing of medical record number. The patients in the control group were treated with Letrozole tablets, and the patients in the observation group were treated with Letrozole tablets combined with Menotrophin, and the sex hormone levels, ovulation rate, the number of mature follicles, endometrial thickness, pregnancy rate, and early miscarriage rate were compared between the two groups. Results: Before treatment, the sex hormone levels of the two groups were compared, and there was no statistical difference (P > 0.05). After treatment, the sex hormone levels of the observation group were all better than those of the control group, and the differences were statistically significant (P < 0.05). The ovulation rate of the observation group was higher than that of the observation group, the number of mature follicles was more than that of the control group, and the endometrial thickness was greater than that of the control group, with statistically significant differences (P < 0.05). The pregnancy rate of the observation group was higher than that of the control group, and the rate of preterm delivery was lower than that of the control group, and the difference was statistically significant (P < 0.05). Conclusion: The combined application of Letrozole tablets and Menotrophin can improve the sex hormone level of PCOS infertility patients, promote their ovulation, improve follicular development, restore the thickness of endometrial lining, and increase the pregnancy rate of the patients and reduce the rate of preterm delivery, which is of value for promotion and application.
Letrozole for Ovulation Induction in Women with Polycystic Ovarian Syndrome: A Systematic Analysis

LIU Zhen,TANG Hui-lin,ZHAI Suo-di

2011-01-01

Abstract:OBJECTIVE To assess the effectiveness and safety of letrozole(LE) for ovulation induction in women with PCOS.METHODS Pubmed,Embase,CNKI,and the Cochrane Library were searched.Randomized controlled trials of letrozole for ovulation induction in women with PCOS were collected.The quality of the retrieved trials was assessed,and meta-analyses were conducted using RevMan software 5.1.RESULTS Six RCTs were included,all of which were published in English.The results of Meta-analyses showed that there were no significant differences between letrozole and clomiphene Citrate in pregnancy rate,ovulation rate,miscarriage rate and adverse event incidence,(1.15[0.86,1.54],1.11[0.91,1.34],1.45[0.52,4.08],0,[-0.01,0.01]).For the patients with BMI<30,letrozole was more effective than clomiphene citrate in pregnancy rate [RR=1.64,95%CI(1.08,2.50)].CONCLUSION Letrozole can be considered as first-line treatment for ovulation induction for patients with BMI<30.According to the guideline,the lifestyle should be modified before treatment for patients with BMI>30.Due to insufficient evidence available in the literature,more large scale,good-designed RCTs are needed to confirm whether letrozole can be used as first-line drug.

[Happiness and the meaning of life].

Comparison the Effectiveness and Safety of Letrozolestimulated and Hormone Replacement Treatment in Endometrial Preparation for Frozen Embryo Transfer in Patients with Polycystic Ovary Syndrome

Letrozole Stimulation in Endometrial Preparation for Cryopreserved–thawed Embryo Transfer in Women with Polycystic Ovarian Syndrome: A Pilot Study

Comparison of Letrozole Versus Combination Letrozole and Clomiphene Citrate (CC) for Ovulation Induction in Sub Fertile Women with Polycystic Ovarian Syndrome (PCOS)—An Open Label Randomized Control Trial

Use of letrozole versus clomiphene citrate combined with gonadotropins for ovulation induction in infertile women with polycystic ovary syndrome: a pilot study

Evaluation of effectiveness of Letrozole in treatment of infertility in women with polycystic ovary syndrome

Trial design and protocol of randomized controlled trial comparing the efficacy of combined letrozole and clomiphene versus only letrozole as a method of ovulation induction in women with polycystic ovarian syndrome (CCLOP trial)

Effects of letrozole alone or in combination with gonadotropins on ovulation induction and clinical pregnancy in women with polycystic ovarian syndrome: a systematic review and meta-analysis of randomized controlled trials

Comparison of Letrozole and Clomiphene Citrate in Pregnancy Outcomes in Patients with Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis

Adrenergic stimulation of vascular prostacyclin: role of alpha 1-receptors in smooth muscle cells.

Letrozole combined with low dose highly purified human menopausal gonadotropin for ovulation induction in clomiphene citrate-resistant infertile women with polycystic ovary syndrome:a prospective study

Comparison of clomiphene citrate and letrozole for ovulation induction in women with polycystic ovary syndrome: a prospective randomized trial

Analysis of individualized letrozole therapy for polycystic ovary syndrome patients resistant to clomiphene

[Pharmacobezoar of the stomach as a complication of treatment of duodenal ulcer (author's transl)].

Extended Letrozole Regimen for Treatment of Clomiphene Resistant Polycystic Ovary Syndrome Patients

Comparison the effects of letrozole and clomiphene citrate on the endocrinological profile in women with polycystic ovarian syndrome

Low dose-extended letrozole versus double dose-short letrozole protocol for ovulation induction in polycystic ovary syndrome

Effects of letrozole alone or letrozole in combination with low-dose intramuscular injection of human menopausal gonadotropin on ovulation and pregnancy of 150 patients with polycystic ovary syndrome

Is combined letrozole and clomiphene superior to either as monotherapy: a systemic review and meta-analysis based on clinical trials

Analysis of the Effect of Letrozole Tablets Combined with Menotrophin in the Treatment of Infertility of Polycystic Ovary Syndrome

Letrozole for Ovulation Induction in Women with Polycystic Ovarian Syndrome: A Systematic Analysis